Daisuke Danno

Daisuke Danno

Auto-generated profile, based on publicly available information

Daisuke Danno

Department of Neurology and Headache Center Tominaga Hospital Osaka Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Cephalalgia
Verified
Journal Article
Open access
Masahito KatsukiMasahito Katsuki
Masahito Katsuki
Tomokazu ShimazuTomokazu Shimazu
Tomokazu Shimazu
SKShoji Kikui
Shoji Kikui
DDDaisuke Danno
Daisuke Danno
JMJunichi Miyahara
Junichi Miyahara
TTTakao Takeshima
Takao Takeshima
Background: Misdiagnoses of headache disorders are a serious issue. Therefore, we developed an artificial intelligence-based headache diagnosis model using a large questionnaire database in a specialized headache hospital. Methods: Phase 1: We developed an artificial intelligence model based on a retrospective investigation of 4000 patients (2800 training and 1200 test dataset) diagnosed by headache specialists. Phase 2: The model’s efficacy and accuracy were validated. Five non-headache specialists first diagnosed headaches in 50 patients, who were then re-diagnosed using AI. The ground truth was the diagnosis by headache specialists. The diagnostic performance and concordance rates between headache specialists and non-specialists with or without artificial intelligence were evaluated. Results: Phase 1: The model’s macro-average accuracy, sensitivity (recall), specificity, precision, and F values were 76.25%, 56.26%, 92.16%, 61.24%, and 56.88%, respectively, for the test dataset. Phase 2: Five non-specialists diagnosed headaches without artificial intelligence with 46% overall accuracy and 0.212 kappa for the ground truth. The statistically improved values with artificial intelligence were 83.20% and 0.678, respectively. Other diagnostic indexes were also improved. Conclusions: Artificial intelligence improved the non-specialist diagnostic performance. Given the model’s limitations based on the data from a single center and the low diagnostic accuracy for secondary headaches, further data collection and validation are needed.

27 June 2020 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
DDDaisuke Danno
Daisuke Danno
JWJohanna Wolf
Johanna Wolf
KIKumiko Ishizaki
Kumiko Ishizaki
SKShoji Kikui
Shoji Kikui
HYHiroo Yoshikawa
Hiroo Yoshikawa
TTTakao Takeshima
Takao Takeshima

9 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DDDaisuke Danno
Daisuke Danno
MIMiho Iigaya
Miho Iigaya
Noboru ImaiNoboru Imai
Noboru Imai
HIHisaka Igarashi
Hisaka Igarashi
TTTakao Takeshima
Takao Takeshima
Cefaly (Cefaly Technology, Seraing, Belgium) is a device that stimulates the bilateral supraorbital nerve transcutaneously. A previous study in Europe proved that Cefaly was an effective and safe device as a preventive therapy for migraine. However, there have been no studies on this device in Asia. We examined the safety and preventive effect of Cefaly for migraine. One-hundred patients were prospectively collected from four headache units in Japan. The inclusion criteria were as follows: 18–75 years of age, migraine with and without aura, and at least 2 attacks per month. A 4-week baseline period was followed by 12-week treatment period. The primary end point was the change from baseline in the number of migraine days at 12 weeks. The secondary end points include the changes of the number of migraine attacks, all headache days, acute medicine consumption days and headache severity. After treatment, a questionnaire survey on the satisfaction of the treatment was administered to the patients. The Friedmann test was used to assess the changes between baseline period and after treatment, and Mann-Whitney U test was used for the comparison of efficacy between chronic migraine and episodic migraine, with and without prophylactic treatment or medication overuse. After 12 weeks of treatment, Cefaly use significantly decreased the number of migraine days (8.16 vs. 6.84; p = 0.0036). Only three subjects (3.0%) dropped out due to the adverse effects; however, no serious adverse events were observed. The compliance of this study was very high at 90.0%. Furthermore, a significant decrease was observed in the number of migraine attacks (5.33 vs. 3.94; p = 0.0002) and the intake of acute antimigraine drugs (8.75 vs. 7.83; p = 0.0166). Cefaly is considered to be a safe and highly tolerable effective device for Japanese patients. Trial registration: This study was retrospectively registered to UMIN-CTR(UMIN000033333) on 10 July 2018.

14 March 2022 in BMC Neurology
Verified
Journal Article
Open access
PDF file
DDDaisuke Danno
Daisuke Danno
JWJohanna Wolf
Johanna Wolf
KIKumiko Ishizaki
Kumiko Ishizaki
SKShoji Kikui
Shoji Kikui
KHKoichi Hirata
Koichi Hirata
TTTakao Takeshima
Takao Takeshima
Background: Cranial autonomic symptoms (CASs) during migraine attacks are reported to be quite common regardless of ethnicity. In our previous study investigating 373 migraineurs, we found that 42.4% of them had CASs. The patients with CASs more frequently had cutaneous allodynia than did those without CASs, and we speculated that CASs were associated with central sensitization. The present study searched for substantial evidence on the relationship between CASs and central sensitization in migraine patients. Methods: This was a prospective cross-sectional study. We studied a new independent cohort of 164 migraineurs who presented to the Tominaga Hospital Headache Center from July 2018 until December 2019. The clinical features of CASs according to the criteria in ICHD-3 (beta) were investigated. We also evaluated central sensitization based on the 25 health-related symptoms utilizing the validated central sensitization inventory (CSI), and each symptom was rated from 0 to 4 resulting a total score of 0–100. Results: The mean age was 41.8 (range: 20 to 77) years old. One hundred and thirty-one patients (78.9%) were women. Eighty-six of the 164 (52.4%) patients had at least 1 cranial autonomic symptom. The CSI score of the patients with ≥3 CASs reflected a moderate severity and was significantly higher than in those without CASs (41.9 vs. 30.7, p = 0.0005). The score of the patients with ≥1 conspicuous CAS also reflected a moderate severity and was significantly higher than in those without CASs (40.7 vs. 33.2, p = 0.013). The patients in the CSI ≥40 group had lacrimation, aural fullness, nasal blockage, and rhinorrhea, which are cranial autonomic parasympathetic symptoms, significantly more frequently than those in the CSI < 40 group. Conclusions: Migraine patients with CASs showed significantly greater central sensitization than those without such symptoms. In particular, cranial parasympathetic symptoms were more frequent in centrally sensitized patients than in nonsensitized patients, suggesting that cranial parasympathetic activation may contribute to the maintenance of central sensitization. Trial registration: This study was retrospectively registered with UMIN-CTR on 29 Aug 2020 (UMIN000041603).

27 June 2023 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
DDDaisuke Danno
Daisuke Danno
KIKumiko Ishizaki
Kumiko Ishizaki
SKShoji Kikui
Shoji Kikui
TTTakao Takeshima
Takao Takeshima

1 January 2013 in Internal Medicine
Verified
Journal Article
Closed access
DDDaisuke Danno
Daisuke Danno
KKKeita Kawabata
Keita Kawabata
HTHisao Tachibana
Hisao Tachibana
We herein present three consecutive cases of nummular headache treated with Neurotropin (NTP). Case 1: A 71-year-old man developed a headache in a circumscribed area of the left parietal region. Treatment with NTP resolved the pain after three months. Case 2: A 57-year-old woman developed bifocal pain in both temporal regions. NTP therapy slightly relieved the pain, although the headache remained. Case 3: A 39-year-old man developed bifocal pain the left temporal region. Treatment with NTP resolved the pain after five days. The present results suggest that NTP may be effective for treating patients with nummular headaches.